Risk of gastrointestinal bleeding during anticoagulant treatment.


INTRODUCTION:Gastrointestinal bleeding (GIB) is a major problem in patients on oral anticoagulation therapy. This issue has become even more pressing since the introduction of direct oral anticoagulants (DOACs) in 2009. Areas covered: Here we review current evidence related to GIB associated with oral anticoagulants, focusing on randomized controlled trials, meta-analyses, and post-marketing observational studies. Dabigatran 150 mg twice daily and rivaroxaban 20 mg once daily increase the risk of GIB compared to warfarin. The risk increase with edoxaban is dose-dependent, while apixaban shows apparently, no increased risk. We summarize what is known about GIB risk factors for individual anticoagulants, the location of GIB in patients taking these compounds, and prevention strategies that lower the risk of GIB. Expert opinion: Recently there has been an important shift in the clinical presentation of GIB. Specifically, upper GIB has decreased with the decreased incidence of peptic ulcers due to the broad use of proton pump inhibitors and the decreased prevalence of H. pylori infections. In contrast, the incidence of lower GIB has increased, due in part to colonic diverticular bleeding and angiodysplasia in the elderly. In this population, the addition of oral anticoagulation therapy, especially DOACs, seems to increase the risk of lower GIB.


Expert Opin Drug Saf


Lanas-Gimeno A,Lanas A




Has Abstract


2017-06-01 00:00:00












  • Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures.

    abstract:BACKGROUND:Ximelagatran, the first oral agent in the new class of direct thrombin inhibitors, was withdrawn from the market due to increased rates of liver enzyme elevations in long-term treatments. Despite intensive pre clinical investigations the cellular mechanisms behind the observed hepatic effects remain unknown....

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章


    authors: Ainscow EK,Pilling JE,Brown NM,Orme AT,Sullivan M,Hargreaves AC,Cooke EL,Sullivan E,Carlsson S,Andersson TB

    更新日期:2008-07-01 00:00:00

  • Adverse effects of antiretroviral therapy: focus on orofacial effects.

    abstract::The optimum anti-HIV drug has yet to be found. This paper will summarise some of the oral adverse effects associated with antiretroviral agents against HIV. The development of antiretroviral drugs for the treatment of HIV infection has been aimed at the inactivation of two HIV enzymes: reverse transcriptase and protea...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Diz Dios P,Scully C

    更新日期:2002-11-01 00:00:00

  • Diabetes and fracture healing: the skeletal effects of diabetic drugs.

    abstract:INTRODUCTION:Over 39,000 diabetic patients are surgically treated for trauma and orthopaedic injuries annually in the UK, yet the effects of diabetic medications on the skeletal system is an under researched and under acknowledged field. AREAS COVERED:This review covers all English language novel experimental data rep...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Simpson CM,Calori GM,Giannoudis PV

    更新日期:2012-03-01 00:00:00

  • Antineoplastic drug-induced bradyarrhythmias.

    abstract:INTRODUCTION:Cardiac injury is one of the most impairing side effects of anticancer treatment. The extension of the range of available drugs, the use of combination regimens and the association with radiation therapy have improved life expectancy; however, they have also caused a rising typology of cardiac toxicities, ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Minoia C,Giannoccaro M,Iacobazzi A,Santini D,Silvestris N,Fioretti A,Oliva S,Guarini A

    更新日期:2012-09-01 00:00:00

  • Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data.

    abstract:INTRODUCTION:Cardiovascular (CV) diseases are the leading cause of death and disability in the developed countries. Lipid-lowering therapy is a cornerstone of the CV risk modification strategy. The first line treatment for hyperlipidemia is statins, which decrease low-density lipoprotein cholesterol (LDL-C) by 30-50% a...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Strilchuk L,Fogacci F,Cicero AF

    更新日期:2019-07-01 00:00:00

  • Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis.

    abstract:INTRODUCTION:Although antidepressant (AD) monotherapy is recommended first-line for major depressive disorder (MDD), AD + AD co-treatment is common. AREAS COVERED:We conducted the first systematic review searching PubMed/MEDLINE/PsycInfo/Embase from database inception until 1 June 2015 for acute randomized trials in ≥...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,meta分析,评审


    authors: Galling B,Calsina Ferrer A,Abi Zeid Daou M,Sangroula D,Hagi K,Correll CU

    更新日期:2015-10-01 00:00:00

  • Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials.

    abstract:OBJECTIVE:Further understand the safety profile of celecoxib and provide safety information for important adverse events (AEs). METHODS:Analysis of randomized controlled trials from the Pfizer clinical trial repository (final study reports completed by 31 July 2011) in which celecoxib was compared with placebo or non-...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,meta分析


    authors: Essex MN,Zhang RY,Berger MF,Upadhyay S,Park PW

    更新日期:2013-07-01 00:00:00

  • The safety of JAK kinase inhibitors for the treatment of myelofibrosis.

    abstract:INTRODUCTION:During the last decade, the development of small molecule inhibitors of Janus kinases (JAKi) contributed to revolutionize the therapeutic landscape of myelofibrosis (MF). JAKi proved to be effective in controlling disease-related symptoms and splenomegaly with remarkable inter-drug variability. However, in...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章


    authors: Coltro G,Vannucchi AM

    更新日期:2020-12-27 00:00:00

  • Fracture risk associated with chronic use of bisphosphonates: evidence today.

    abstract:IMPORTANCE OF THE FIELD:Bisphosphonates are the most widely used antiresorptive agents for the treatment of osteoporosis. However, the cumulative bisphoshonate exposure and its association with atypical fragility fractures, and the optimum duration of treatment remain obscure. AREAS COVERED IN THIS REVIEW:This review ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Charopoulos I,Orme S,Giannoudis PV

    更新日期:2011-01-01 00:00:00

  • Methotrexate pulmonary toxicity.

    abstract::Methotrexate is a commonly prescribed antineoplastic and immune modulating compound that has gained wide acceptance in the management of rheumatoid arthritis, psoriasis, sarcoidosis and a number of neoplastic disorders. Although generally considered safe and easy to use, methotrexate has been associated with a number ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Lateef O,Shakoor N,Balk RA

    更新日期:2005-07-01 00:00:00

  • Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects.

    abstract::Bone morphogenetic proteins (BMPs) have been extensively studied since the discovery of agents within bone that could induce bone formation at ectopic sites by Urist in the 1960s. Extensive preclinical research has been carried out showing the efficacy of these products in promoting bone healing. Clinical trials are e...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Harwood PJ,Giannoudis PV

    更新日期:2005-01-01 00:00:00

  • Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.

    abstract:INTRODUCTION:The antimalarial drug hydroxychloroquine (HCQ) is widely used to treat various rheumatic diseases. Many autoimmune diseases occur in women of child-bearing age who may become pregnant while on therapy, which raises concerns regarding the teratogenicity of HCQ and its effect on the outcome of the pregnancy....

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Abarientos C,Sperber K,Shapiro DL,Aronow WS,Chao CP,Ash JY

    更新日期:2011-09-01 00:00:00

  • A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine.

    abstract::Background: Erenumab has recently been approved as a pharmacological treatment for the prevention of migraine. However, the incidence estimates of adverse drug reactions (ADRs) were not consistent among studies. Consequently, pooled measures of the incidences of ADRs that accounts for inter-study heterogeneity are des...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章


    authors: Pellesi L,De Icco R,Alawie HY,Andersen M,Liang D,Amirguliyev S,Al-Karagholi MA,Amin FM,Sessa M

    更新日期:2020-12-29 00:00:00

  • The safety and efficacy of antithyroid drugs.

    abstract::Thionamides, selective inhibitors of thyroid peroxidase-mediated iodination by tyrosine residues in thyroglobulin, have been effectively used in the treatment of hyperthyroidism. The choices for initial treatment of patients with Graves' disease differ in various countries, and many physicians around the world prefer ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Azizi F

    更新日期:2006-01-01 00:00:00

  • Monitoring self-medication.

    abstract::Self-medication, using non-prescription drugs, is beneficial to patients, healthcare professionals, the pharmaceutical industry and governments. Although many non-prescription medications are effective, misuse and abuse of these products can arise. Monitoring of specific populations and products, in addition to data r...

    journal_title:Expert opinion on drug safety

    pub_type: 社论


    authors: Hughes CM

    更新日期:2003-01-01 00:00:00

  • A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.

    abstract::Worldwide, women comprise > 50% of all people living with HIV and the vast majority of these women are of childbearing age. In fact, a significant proportion of these women are identified as HIV-infected during pregnancy. Preventing perinatal transmission has been one of the greatest prevention successes of the HIV ep...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Nurutdinova D,Overton ET

    更新日期:2009-11-01 00:00:00

  • Drug safety evaluation of alemtuzumab for multiple sclerosis.

    abstract:INTRODUCTION:Alemtuzumab is a humanised anti-CD52 mAb which has recently been licensed for the treatment of relapsing multiple sclerosis in Europe. AREAS COVERED:The efficacy and safety of alemtuzumab from open label, Phase II and Phase III trials is reported. EXPERT OPINION:Alemtuzumab causes rapid and profound comp...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Willis M,Robertson NP

    更新日期:2014-08-01 00:00:00

  • Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.

    abstract:OBJECTIVES:To describe the cumulative incidences of adverse drug reactions (ADRs) associated with disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients from real-world data (RWD), using the DREAM-RA registry, and to compare these with incidence frequencies mentioned in the Summary of Pro...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章


    authors: Giraud EL,Jessurun NT,van Hunsel FPAM,van Puijenbroek EP,van Tubergen A,Ten Klooster PM,Vonkeman HE

    更新日期:2020-12-01 00:00:00

  • Safety of available and emerging drug therapies for hyperhidrosis.

    abstract:INTRODUCTION:Hyperhidrosis affects 4.8% of the U.S. population and has been underestimated by physicians for long time despite considerable interference with quality of life. Many patients suffer from primary (idiopathic) hyperhidrosis which results from over-activity of sympathetic nerves and is restricted to specific...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Hosp C,Hamm H

    更新日期:2017-09-01 00:00:00

  • The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.

    abstract::Ixabepilone is a semisynthetic analogue of epothilone B, a novel microtubule-stabilizing agent. Preclinical data suggest that its mechanisms of actions are different from those of the most commonly used microtubule-stabilizing agent, paclitaxel. This information in addition to the cytotoxicity of this drug in taxane-r...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Gupta D,Mani S

    更新日期:2009-01-01 00:00:00

  • Adrenaline in anaphylaxis treatment. Balancing benefits and harms.

    abstract:INTRODUCTION:Although anaphylaxis is a relatively common disorder, clinicians and scientists have debated on how to best define and manage this condition. The current recommendations are focused on the central role of adrenaline, but evidence in support of this therapeutic approach is modest, mainly for the lack of wel...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章


    authors: Cervellin G,Sanchis-Gomar F,Lippi G

    更新日期:2016-06-01 00:00:00

  • The safety of available treatments options for neuroendocrine tumors.

    abstract:INTRODUCTION:Neuroendocrine neoplasms (NEN) represent a heterogeneous group of malignancies generally characterized by low proliferation and indolent course. However, about half of the newly diagnosed cases are metastatic and require long-term systemic therapies. Areas covered: This review revises the literature to sum...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Faggiano A,Lo Calzo F,Pizza G,Modica R,Colao A

    更新日期:2017-10-01 00:00:00

  • Current strategies for managing intestinal failure-associated liver disease.

    abstract::Introduction: Intestinal failure-associated liver disease (IFALD) refers to hepatic dysfunction that results from prolonged parenteral nutrition (PN) use. IFALD is multifactorial in origin and remains a major cause of morbidity and mortality. Prior to 2004, IFALD was associated with mortality as high as 90% in infants...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章


    authors: Secor JD,Yu L,Tsikis S,Fligor S,Puder M,Gura KM

    更新日期:2020-12-30 00:00:00

  • The safety of albiglutide for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Rendell MS

    更新日期:2017-09-01 00:00:00

  • The safety of pharmacological treatment options for lupus nephritis.

    abstract:INTRODUCTION:The management of lupus nephritis (LN) has changed significantly over the last 10 years due to emerging evidence from large randomised clinical trials that produced good quality data and guided the formulation of two key concepts: the induction of remission and the maintenance phase of immunosuppressive th...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Velo-García A,Ntatsaki E,Isenberg D

    更新日期:2016-08-01 00:00:00

  • Drugs with anticholinergic properties: a current perspective on use and safety.

    abstract:INTRODUCTION:Many commonly used drugs have primary or secondary anticholinergic effects contributing to adverse outcomes ranging from mild-to-severe to potentially lethal. Anticholinergic adverse effects frequently occur with medications prescribed with other intended mechanisms of action, including antihistamines, ant...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Gerretsen P,Pollock BG

    更新日期:2011-09-01 00:00:00

  • Application of botulinum toxin in pregnancy and its impact on female reproductive health.

    abstract::Introduction: Botulinum toxin (BoNT) is a protein secreted by the anaerobic Gram-negative bacterium Clostridium botulinum. Among the seven known subtypes, type A is the most commonly used in women to treat diseases. It primarily blocks presynaptic release of acetylcholine at the neuromuscular junction, resulting in te...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Li W,Tang M

    更新日期:2020-01-01 00:00:00

  • The safety of black cohosh (Actaea racemosa, Cimicifuga racemosa).

    abstract::Black cohosh (Actaea racemosa/Cimicifuga racemosa) is a North American perennial plant that has been used for traditional medicinal purposes by the native Indian population. Its modern day application is the treatment of menopausal symptoms. Unlike conventional non-herbal medications, herbal preparations have not been...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Huntley A

    更新日期:2004-11-01 00:00:00

  • The safety of lanreotide for neuroendocrine tumor.

    abstract:INTRODUCTION:Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor. Its action is mediated by its affinity to somatostatin receptors, especially sst2 and ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Godara A,Siddiqui NS,Byrne MM,Saif MW

    更新日期:2019-01-01 00:00:00

  • Typical toxic components in traditional Chinese medicine.

    abstract:INTRODUCTION:Traditional Chinese medicine (TCM) is widely used around the world. However, with its wide use has been the identification of a number of toxicological issues that have severely restricted its use in clinical treatment. The identification of these toxic substances within TCM has become somewhat of a hot to...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审


    authors: Lv W,Piao JH,Jiang JG

    更新日期:2012-11-01 00:00:00